We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs.

Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053

Back us on Patreon! www.patreon.com/plenarysession

We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs. Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053 Back us on Patreon! www.patreon.com/plenarysession

1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Medicine

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service. A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, &amp; health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Share 1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

Sign up to save your podcasts

1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

More shows like Plenary Session - inactive due to federal service

The Moth

The Joe Rogan Experience

FoundMyFitness

JAMA Clinical Reviews

My Favorite Murder with Karen Kilgariff and Georgia Hardstark

Pod Save America

The Daily

Up First from NPR

TRIGGERnometry

Conan O’Brien Needs A Friend

The Megyn Kelly Show

The Ezra Klein Show

Sensible Medicine

The Tucker Carlson Show

FDA Direct